Research papers of the week – January 10, 2022

Mateusz Sokolski, Konrad Reszka, Tomasz Suchocki, Barbara Adamik, Adrian Doroszko, Jarosław Drobnik, Joanna Gorka-Dynysiewicz, Maria Jedrzejczyk, Krzysztof Kaliszewski, Katarzyna Kilis-Pstrusinska, Bogusława Konopska, Agnieszka Kopec, Anna Larysz, Weronika Lis, Agnieszka Matera-Witkiewicz, Lilla Pawlik-Sobecka, Marta Rosiek-Biegus, Justyna M. Sokolska, Janusz Sokolowski, Anna Zapolska-Tomasiewicz, Marcin Protasiewicz, Katarzyna Madziarska, Ewa A. Jankowska

Journal of Clinical Medicine

Ministerial score = 140.0
JIF Impact Factor (2020) = 4.242 (Q1)

Background: Patients with heart failure (HF) are at high risk of unfavorable courses of COVID-19. The aim of this study was to evaluate characteristics and outcomes of COVID-19 patients with HF. Methods: Data of patients hospitalized in a tertiary hospital in Poland between March 2020 and May 2021 with laboratory-confirmed COVID-19 were analyzed. The study population was divided into a HF group (patients with a history of HF) and a non-HF group. Results: Out of 2184 patients (65 ± 13 years old, 50% male), 12% had a history of HF. Patients from the HF group were older, more often males, had more comorbidities, more often dyspnea, pulmonary and peripheral congestion, inflammation, and end-organ damage biomarkers. HF patients had longer and more complicated hospital stay, with more frequent acute HF development as compared with non-HF. They had significantly higher mortality assessed in hospital (35% vs. 12%) at three (53% vs. 22%) and six months (72% vs. 47%). Of 76 (4%) patients who developed acute HF, 71% died during hospitalization, 79% at three, and 87% at six months. Conclusions: The history of HF identifies patients with COVID-19 who are at high risk of in-hospital complications and mortality up to six months of follow-up.

DOI:10.3390/jcm11010241

READ THE PAPER UPWr Base